Dr. Xue has more than 10 years of experience in the R&D, production, and domestic & international cooperation of biotechnology drugs, innovative small molecule drugs, and ADC drugs.
Management: With more than 1,000 people of management experience, covering the design and screening of macromolecular and small molecule drugs, process development and scale-up, pharmacology and toxicology research, clinical development, production, and the company's transnational operations.
Project development: including biosimilars and different types of innovative drugs, 2 varieties have been successfully launched, and more than 10 projects are in different stages of clinical trials, many of which are simultaneously conducting clinical trials in China and the United States. In terms of ADCs, different generations of technologies and different types of targets are involved, including HER2, TROP2, etc., as well as a series of more innovative targets.
Intellectual property rights: more than 100 applications, involving China, the United States, Europe and other countries and regions, of which nearly 20 have been authorized.
Business cooperation: reached a number of external licensing cooperation, involving more than 1 billion US dollars.
Dr. Cai is the cofounder and served as chief scientific officer of MediLink Therapeutics. Before cofounding Medilink Therapeutics, Dr. Cai served as vice general manager and director of chemistry of Shanghai Hansoh Pharm. Before joining Hansoh, Dr Cai was deputy general manager of Sichuan Kelun Institute of Pharmaceutical Research responsible for small molecule drug R&D and Kelun’s innovation centre managing over 250 research scientists. Dr. Cai accumulated over 30 years of experience in drug discovery research, managed over 100 projects across different therapeutic areas with 30 compounds in different stages of clinical development, 8 of them are antibody drug conjugates, including SKB264, SKB315, YL201 and YL202.
Dr. Cai graduated from Dalian Institute of Chemical Physics with PhD degree, finished post-doctoral training at University College London. Before returning to China, Dr. Cai was senior team leader and project leader at Merck’s (MSD) UK research centre.
Dr. Xiao is primarily responsible for ADC drug preclinical development and external cooperation in business development at MediLink. With 16 years of experience in both academia and the biopharmaceutical industry, Dr. Xiao previously served as the VP of Biologics R&D at Kelun-Biotech, where he was responsible for the development of multiple innovative biologics from 2013 to 2020. Several of these projects achieved global licensing agreements with multinational companies, totaling over $12 billion.
He has led 15 monoclonal antibody/bispecific antibody/ADC projects into clinical stages, with two monoclonal antibody project and one ADC project submitted for BLA. Additionally, one ADC projects is in Phase III clinical stage, and four ADC projects are in Phase I clinical stage.
Bachelor's degree in Life Sciences from the University of Science and Technology of China and Ph.D. degree in Chemical Engineering from the University of Southern California.